Commodore Capital LP Protagonist Therapeutics, Inc Transaction History

Commodore Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $2.34 Million - $8.47 Million	-331,886 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $11.1 Million - $17.1 Million	-473,687 Reduced 58.8%	331,886 $7.86 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $5.42 Million - $11.4 Million	307,494 Added 61.74%	805,573 $27.6 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $3.72 Million - $14.3 Million	287,479 Added 136.5%	498,079 $8.83 Million
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $3.55 Million - $6.24 Million	-139,000 Reduced 39.76%	210,600 $9.45 Million
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $39,942 - $65,415	2,100 Added 0.6%	349,600 $9.06 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $6.43 Million - $8.73 Million	347,500 New	347,500 $7.01 Million

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.